These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 19861436)
1. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Byers LA; Sen B; Saigal B; Diao L; Wang J; Nanjundan M; Cascone T; Mills GB; Heymach JV; Johnson FM Clin Cancer Res; 2009 Nov; 15(22):6852-61. PubMed ID: 19861436 [TBL] [Abstract][Full Text] [Related]
2. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Johnson FM; Saigal B; Tran H; Donato NJ Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553 [TBL] [Abstract][Full Text] [Related]
3. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Sen B; Saigal B; Parikh N; Gallick G; Johnson FM Cancer Res; 2009 Mar; 69(5):1958-65. PubMed ID: 19223541 [TBL] [Abstract][Full Text] [Related]
4. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Haura EB; Zheng Z; Song L; Cantor A; Bepler G Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287 [TBL] [Abstract][Full Text] [Related]
5. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409 [TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387 [TBL] [Abstract][Full Text] [Related]
7. Tescalcin/c-Src/IGF1Rβ-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1. Lee JH; Choi SI; Kim RK; Cho EW; Kim IG Sci Rep; 2018 Jul; 8(1):10711. PubMed ID: 30013043 [TBL] [Abstract][Full Text] [Related]
8. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630 [TBL] [Abstract][Full Text] [Related]
9. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib. Wang J; Wang Y; Zheng C; Hou K; Zhang T; Qu X; Liu Y; Kang J; Hu X; Che X Cell Biol Int; 2018 Sep; 42(10):1292-1299. PubMed ID: 29885023 [TBL] [Abstract][Full Text] [Related]
11. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152 [TBL] [Abstract][Full Text] [Related]
12. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308 [TBL] [Abstract][Full Text] [Related]
13. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Johnson FM; Saigal B; Talpaz M; Donato NJ Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784 [TBL] [Abstract][Full Text] [Related]
14. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507 [TBL] [Abstract][Full Text] [Related]
15. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation. Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787 [TBL] [Abstract][Full Text] [Related]
16. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells. Chen B; Xu X; Luo J; Wang H; Zhou S PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184 [TBL] [Abstract][Full Text] [Related]
17. The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion. Cheng E; Whitsett TG; Tran NL; Winkles JA Mol Cancer Res; 2015 Mar; 13(3):575-83. PubMed ID: 25392346 [TBL] [Abstract][Full Text] [Related]
18. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201 [TBL] [Abstract][Full Text] [Related]
19. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Song L; Turkson J; Karras JG; Jove R; Haura EB Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138 [TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]